Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Public ClinicalTrials.gov record NCT04319198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
Study identification
- NCT ID
- NCT04319198
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab Govitecan-hiy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2020
- Primary completion
- Oct 17, 2024
- Completion
- Oct 17, 2024
- Last update posted
- Sep 29, 2025
2020 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| Christiana Care Health Services, Christiana Hospital | Newark | Delaware | 19718 | — |
| Florida Cancer Specialists & Research Institute | Fort Myers | Florida | 33905 | — |
| Baptist Health - Miami Cancer Institute | Miami | Florida | 33176 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of MD Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| New York Cancer & Blood Specialists - Setauket Medical Oncology | Port Jefferson | New York | 11776 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15213 | — |
| Next Oncology | Austin | Texas | 78758 | — |
| Oncology Consultants,P.A. | Houston | Texas | 77024 | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04319198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04319198 live on ClinicalTrials.gov.